Tumor Biology

, Volume 37, Issue 2, pp 1803–1815 | Cite as

Apoptotic effects of non-edible parts of Punica granatum on human multiple myeloma cells

  • Yağmur Kiraz
  • Vidushi S. Neergheen-Bhujun
  • Nawraj Rummun
  • Yusuf Baran
Original Article


Multiple myeloma is of great concern since existing therapies are unable to cure this clinical condition. Alternative therapeutic approaches are mandatory, and the use of plant extracts is considered interesting. Punica granatum and its derived products were suggested as potential anticancer agents due to the presence of bioactive compounds. Thus, polypenolic-rich extracts of the non-edible parts of P. granatum were investigated for their antiproliferative and apoptotic effects on U266 multiple myeloma cells. We demonstrated that there were dose-dependent decreases in the proliferation of U266 cells in response to P. granatum extracts. Also, exposure to the extracts triggered apoptosis with significant increases in loss of mitochondrial membrane potential in U266 cells exposed to the leaves and stem extracts, while the flower extract resulted in slight increases in loss of MMP. These results were confirmed by Annexin-V analysis. These results documented the cytotoxic and apoptotic effects of P. granatum extracts on human U266 multiple myeloma cells via disruption of mitochondrial membrane potential and increasing cell cycle arrest. The data suggest that the extracts can be envisaged in cancer chemoprevention and call for further exploration into the potential application of these plant parts.


Apoptosis Cytotoxicity Multiple myeloma Pomegranate 


  1. 1.
    Long JS, Ryan KM. New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy. Oncogene. 2012;31:5045–60.CrossRefPubMedGoogle Scholar
  2. 2.
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:7–70.CrossRefGoogle Scholar
  3. 3.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.CrossRefPubMedGoogle Scholar
  4. 4.
    Bode AM, Dong Z. Targeting signal transduction pathways by chemopreventive agents. Mutat Res. 2004;555:33–51.CrossRefPubMedGoogle Scholar
  5. 5.
    Chun KS, Surh YJ. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol. 2004;68:1089–100.CrossRefPubMedGoogle Scholar
  6. 6.
    Kundu JK, Surh YJ. Breaking the relay in deregulated cellular signal transduction as a rationale for chemoprevention with anti-inflammatory phytochemicals. Mutat Res. 2005;591:123–46.CrossRefPubMedGoogle Scholar
  7. 7.
    Neergheen VS, Bahorun T, Taylor EW, Jen LS, Aruoma OI. Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicology. 2010;278:229–41.CrossRefPubMedGoogle Scholar
  8. 8.
    Jurenka JS. Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern Med Rev. 2008;13:128–44.PubMedGoogle Scholar
  9. 9.
    Ana F, Calhau C. The bioactivity of pomegranate: impact on health and disease. Crit Rev Food Sci Nutr. 2011;51:626–34.CrossRefGoogle Scholar
  10. 10.
    Guy R, Guého J. Les Plantes et Leur Histoire À l’Ile Maurice. Mauritius: S.n. 1999.Google Scholar
  11. 11.
    Vera-Ku M, Martha MG, Rosa MP, Miguel RV, Paulino SP, Roberto CR, et al. Medicinal potions used against infectious bowel diseases in Mayan traditional medicine. J Ethnopharmacol. 2010;132:303–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Tetali P, Waghchaure C, Daswani PG, Antia NH, Birdi TJ. Ethnobotanical survey of antidiarrhoeal plants of Parinche Valley, Pune District, Maharashtra, India. J Ethnopharmacol. 2009;123:229–36.CrossRefPubMedGoogle Scholar
  13. 13.
    Adams LS, Zhang Y, Seeram NP, Heber D, Chen S. Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro. Cancer Prev Res (Phila). 2010;3:108–13.CrossRefGoogle Scholar
  14. 14.
    Haidari M, Ali M, Ward Casscells S, Madjid M. Pomegranate (Punica granatum) purified polyphenol extract inhibits influenza virus and has a synergistic effect with oseltamivir. Phytomedicine. 2009;16:1127–36.CrossRefPubMedGoogle Scholar
  15. 15.
    Endo EH, Cortez DA, Ueda-Nakamura T, Nakamura CV, Dias Filho BP. Potent antifungal activity of extracts and pure compound isolated from pomegranate peels and synergism with fluconazole against Candida albicans. Res Microbiol. 2010;161:534–40.CrossRefPubMedGoogle Scholar
  16. 16.
    Dahlawi H, Jordan-Mahy N, Clench M, McDougall GJ, Maitre CL. Polyphenols are responsible for the proapoptotic properties of pomegranate juice on leukemia cell lines. Food Sci Nutr. 2013;1:196–208.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zhang L, Quanjuan Fu Q, Zhang Y. Composition of anthocyanins in pomegranate flowers and their antioxidant activity. Food Chem. 2011;127:1444–49.CrossRefGoogle Scholar
  18. 18.
    Lansky EP, Newman RA. Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J Ethnopharmacol. 2007;109:177–206.CrossRefPubMedGoogle Scholar
  19. 19.
    Jeune MA, Kumi-Diaka J, Brown J. Anticancer activities of pomegranate extracts and genistein in human breast cancer cells. J Med Food. 2005;8:469–75.CrossRefPubMedGoogle Scholar
  20. 20.
    Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res. 2006;12:4018–26.CrossRefPubMedGoogle Scholar
  21. 21.
    Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, et al. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer P D. 2013;16:50–5.CrossRefGoogle Scholar
  22. 22.
    Ampasavate C, Okonogi S, Anuchapreeda S. Cytotoxicity of extracts from fruit plants against leukemic cell lines. Afr J Pharm Pharmacol. 2010;4:13–21.Google Scholar
  23. 23.
    Dahlawi H, Jordan-Mahy N, Clench M, Le Maitre CL. Bioactive actions of pomegranate fruit extracts on leukemia cell lines in vitro hold promise for new therapeutic agents for leukemia. Nutr Cancer. 2012;64:100–10.CrossRefPubMedGoogle Scholar
  24. 24.
    Rummun N, Somanah J, Ramsaha S, Bahorun T, Neergheen-Bhujun VS. Bioactivity of nonedible parts of Punica granatum L.: a potential source of functional ingredients. Int J Food Sci. 2013;1–12.Google Scholar
  25. 25.
    Baran Y, Bielawski J, Gunduz U, Ogretmen B. Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation. J Cancer Res Clin Oncol. 2011;137:1535–44.CrossRefPubMedGoogle Scholar
  26. 26.
    Gencer EB, Ural AU, Avcu F, Baran Y. A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes. Ann Hematol. 2011;90:1265–75.CrossRefPubMedGoogle Scholar
  27. 27.
    De la Puente P, Muz B, Azab F, Luderer M, Azab AK. Molecularly targeted therapies in multiple myeloma. Leuk Res Treat. 2014;2014:1–8.CrossRefGoogle Scholar
  28. 28.
    Kinghorn AD, Farnsworth NR, Soejarto DD, Cordell GA, Pezzuto JM, Udeani GO, et al. Novel strategies for the discovery of plant-derived anticancer agents. Pure Appl Chem. 1999;71:1611–18.CrossRefGoogle Scholar
  29. 29.
    Bekir J, Mars M, Souchard JP, Bouajila J. Assessment of antioxidant, anti-inflammatory, anti-cholinesterase and cytotoxic activities of pomegranate (Punica granatum) leaves. Food Chem Toxicol. 2013;55:470–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Lucci P, Pacetti D, Loizzo MR, Frega NG. Punica granatum cv. Dente Di Cavallo seed ethanolic extract: antioxidant and antiproliferative activities. Food Chem. 2015;167:475–83.CrossRefPubMedGoogle Scholar
  31. 31.
    Orgil O, Schwartz E, Baurch L, Matityahu I, Mahajna J, Amir R. The antioxidative and anti-proliferative potential of non-edible organs of the pomegranate fruit and tree. LWT-Food Sci Technol. 2014;58:571–7.CrossRefGoogle Scholar
  32. 32.
    Aqil F, Munagala R, Vadhanam MV, Kausar H, Jeyablan J, Schultz DJ, et al. Anti-proliferative activity and protection against oxidative DNA damage by punicalagin isolated from pomegranate husk. Food Res Int. 2012;49:345–53.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Bishayee A, Thoppil RJ, Darvesh AS, Ohanyan V, Meszaros JG. Pomegranate phytoconstituents blunt the inflammatory cascade in a chemically induced rodent model of hepatocellular carcinogenesis. J Nutr Biochem. 2013;24:178–87.CrossRefPubMedGoogle Scholar
  34. 34.
    Hong MY, Seeram NP, Heber D. Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. J Nutr Biochem. 2008;19:848–55.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Koyama S, Cobb LJ, Mehta HH, Seeram NP, Heber D, Pantuck AJ, et al. Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. Growth Hormon IGF Res. 2010;20:55–62.CrossRefGoogle Scholar
  36. 36.
    Ming DS, Pham S, Deb S, Chin MY, Kharmate G, Adomat H, et al. Pomegranate extracts impact the androgen biosynthesis pathways in prostate cancer models in vitro and in vivo. J Steroid Biochem Mol Biol. 2014;143:19–28.CrossRefPubMedGoogle Scholar
  37. 37.
    Sreeja S, Santhosh Kumar TR, Lakshmi BS, Sreeja S. Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation. J Nutr Biochem. 2012;23:725–32.CrossRefPubMedGoogle Scholar
  38. 38.
    Wang L, Ho J, Glackin C, Martins-Green M. Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis. Transl Oncol. 2012;5:344–55.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Shahneh FZ, Baradaran B, Orangi M, Zamani F. In vitro cytotoxic and apoptotic activity of four Persian medicine plants on human leukemia and lymphoma cells. Asian Pac J Trop Dis. 2014;4:415–20.CrossRefGoogle Scholar
  40. 40.
    Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 2003;4:721–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432:316–23.CrossRefPubMedGoogle Scholar
  42. 42.
    Schwartz GK, Shah M. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol. 2005;23:9408–21.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Yağmur Kiraz
    • 1
    • 2
  • Vidushi S. Neergheen-Bhujun
    • 3
  • Nawraj Rummun
    • 3
  • Yusuf Baran
    • 1
    • 2
  1. 1.Department of Molecular Biology and GeneticsIzmir Institute of TechnologyIzmirTurkey
  2. 2.Department of Molecular Biology and Genetics, Faculty of Life and Natural SciencesAbdullah Gul UniversityKayseriTurkey
  3. 3.Department of Health Sciences, Faculty of Science and ANDI Centre of Excellence for Biomedical and Biomaterials ResearchUniversity of MauritiusMokaMauritius

Personalised recommendations